GeneDx Holdings (WGS) Net Cash Flow (2020 - 2026)

GeneDx Holdings has disclosed Net Cash Flow across 7 years of filings, most recently posting -$11.1 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 176.41% year-over-year to -$11.1 million; the TTM figure through Mar 2026 stood at -$5.8 million (down 136.04% YoY), while the FY2025 annual figure was $19.8 million, up 236.78% from the prior year.
• Net Cash Flow retreated to -$11.1 million in Q1 2026, from $9.0 million in the prior quarter.
• Over the last five years, Net Cash Flow for WGS reached as high as $76.6 million in Q1 2023 and fell as low as -$93.3 million in Q3 2022.
• The 5-year median for Net Cash Flow is -$16.0 million (2024), against an average of -$18.0 million.
• Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 239.85% — and 2025, when it jumped 1101.76%.
• A 5-year view of Net Cash Flow shows it stood at -$67.4 million in 2022, then surged by 118.36% to $12.4 million in 2023, then jumped by 120.67% to $27.3 million in 2024, then sank by 66.94% to $9.0 million in 2025, then slumped by 222.61% to -$11.1 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$11.1 million, $9.0 million, and $21.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.